Form 4: Research Frontiers Director Alexander Kaganowicz Acquires 45,000 Stock Options

Director Alexander Kaganowicz of Research Frontiers Inc. was granted 45,000 stock options on December 31, 2024, contingent on shareholder approval.

Summary

• Alexander Kaganowicz, a director at Research Frontiers Inc., was granted 45,000 stock options on December 31, 2024.
• These options have an exercise price of $1.68 per share and expire on December 30, 2034.
• The grant of 27,950 of these options is contingent on shareholder approval at the 2025 Annual Meeting of Stockholders for additional shares under the 2019 Equity Incentive Plan.
• If shareholder approval is not obtained, these 27,950 contingent options will automatically terminate.
• Following this transaction, Mr. Kaganowicz directly owns 327,495 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate practice of granting stock options to a director, which is generally viewed positively as it aligns interests. The contingency on shareholder approval introduces a minor element of uncertainty, but overall the sentiment is positive.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The long expiration date of the options (December 30, 2034) provides a long-term incentive for the director.

Negatives

• The grant of 27,950 options is contingent on shareholder approval, introducing uncertainty.

Risks

• The contingent options could terminate if shareholder approval is not obtained at the 2025 Annual Meeting of Stockholders.
• The value of the options is dependent on the future performance of the company's stock price.

Future Outlook

The grant of 27,950 options is contingent on shareholder approval at the 2025 Annual Meeting of Stockholders.

Industry Context

Stock option grants are a common practice for incentivizing directors and aligning their interests with shareholders in publicly traded companies.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors in publicly listed companies.
• The vesting and expiration terms are typical for such grants, often spanning several years to encourage long-term value creation.
• The contingency on shareholder approval for a portion of the options is a measure to ensure alignment with shareholder interests and is not uncommon.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with their own.
• The contingent nature of some options may introduce a degree of uncertainty for shareholders.

Next Steps

• Shareholder approval will be sought at the 2025 Annual Meeting of Stockholders for the additional shares required for the contingent options.

Key Dates

Keywords

stock options, equity incentive plan, director, shareholder approval, derivative securities, Research Frontiers Inc, REFR